By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Anti-angiogenic ophthalmic agents > Aflibercept ophthalmic > Aflibercept Ophthalmic Dosage
Anti-angiogenic ophthalmic agents
https://themeditary.com/dosage-information/aflibercept-ophthalmic-dosage-7442.html

Aflibercept Ophthalmic Dosage

Drug Detail:Aflibercept ophthalmic (Aflibercept ophthalmic [ a-flib-er-sept-off-thal-mik ])

Drug Class: Anti-angiogenic ophthalmic agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Macular Degeneration

2 mg via intravitreal injection every 4 weeks for the first 12 weeks, then 2 mg via intravitreal injection every 8 weeks

  • Some patients may need to continue with every 4-week dosing after the first 12 weeks

Comments:
  • Patients should be assessed regularly.
  • Additional efficacy was not demonstrated for most patients when dosed every 4 weeks compared to every 8 weeks; however, some patients may need monthly dosing.
  • After 1 year of effective therapy, patients may be treated with 2 mg via intravitreal injection every 12 weeks, although this regimen is not as effective as the recommended every 8-week dosing regimen.

Use: For the treatment of neovascular (wet) age-related macular degeneration.

Usual Adult Dose for Macular Edema

Macular Edema following Retinal Vein Occlusion (RVO):
2 mg via intravitreal injection every 4 weeks

Diabetic Macular Edema (DME):
2 mg via intravitreal injection every 4 weeks for the first 5 injections (20 weeks), then 2 mg via intravitreal injection every 8 weeks

  • Some patients may need to continue with every 4-week dosing after the first 20 weeks

Diabetic Retinopathy (DR):
2 mg via intravitreal injection every 4 weeks for the first 5 injections (20 weeks), then 2 mg via intravitreal injection every 8 weeks
  • Some patients may need to continue with every 4-week dosing after the first 20 weeks

Comments:
  • Patients should be assessed regularly.
  • Additional efficacy was not demonstrated for most patients when dosed every 4 weeks compared to every 8 weeks; however, some patients may need monthly dosing.

Uses: For the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to the active component or any of the ingredients
  • Ocular or periocular infections
  • Active intraocular inflammation

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

ADMINISTRATION ADVICE:
For ophthalmic intravitreal injection

  • This drug should only be administered by a qualified physician
  • The procedure should be performed under aseptic conditions to include surgical hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent); adequate anesthesia and a topical broad-spectrum microbicide should be given prior to the injection

Reconstitution/preparation techniques:
  • Refer to the manufacturer product information for preparation instructions
  • The product should be inspected visually prior to administration; if particulates, cloudiness, or discoloration are visible, the vial should not be used
  • Each vial is for the treatment of a single eye

Storage requirements:
  • Store in a refrigerator 36F to 46F (2C to 8C); do not freeze
  • Protect from light; store in original carton until ready to use

Monitoring:
  • Monitor for increased intraocular pressure and perfusion of the optic nerve head
  • Monitor for endophthalmitis and retinal detachment (e.g., eye pain, redness of the eye, photophobia, blurring of vision)

Patient advice:
  • Patients should be informed that they are at risk of developing endophthalmitis or retinal detachment and they should seek immediate care from an ophthalmologist if their eye becomes red, sensitive to light, painful, or develops a change in vision.
  • Patients should be advised not to drive or use machinery until visual function has recovered sufficiently from the procedure and associated eye exams.
  • Women of childbearing potential should be advised to use effective contraception prior to the initial dose, during treatment, and for at least 3 months after the last injection.

Frequently asked questions

  • What’s the difference between Eylea and Avastin?
  • Does Eylea raise blood pressure?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by